Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 448 of 5804
-
New study tracks how well alectinib keeps lung cancer from returning after surgery
Disease control Recruiting nowThis study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy i…
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could CAR t-cells tame myasthenia gravis? early trial launches
Disease control Recruiting nowA Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to shrink tough lung tumors
Disease control Recruiting nowThe aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Phase: PHASE2 • Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a different dosing schedule improve breast cancer treatment?
Disease control Recruiting nowThe goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerabil…
Phase: PHASE1, PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo aims to slash heart disease risk by targeting hidden cholesterol
Disease control Recruiting nowThe purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density li…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can one week of radiation beat two for breast cancer?
Disease control Recruiting nowThis study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an …
Phase: PHASE3 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New strategy aims to stop eye muscle disease from spreading
Disease control Recruiting nowMyasthenia is an autoimmune disease causing dysfunction of the neuromuscular junction, resulting in fluctuating and variable muscle weakness. In the initial phase of the disease, 70% of patients present with ocular onset myasthenia (OMG), i.e. weakness limited to the oculomotor …
Phase: PHASE3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on autoimmune disease
Disease control OngoingThis is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Phase: PHASE1 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radio…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo aims to shrink lung tumors before surgery
Disease control Recruiting nowThis phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC). The current standard of care (SOC) for NSCLC is to give chemotherapy and im…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New heart valve procedure could help patients with leaky aortic valve
Disease control Recruiting nowThis study is a prospective, multicenter, non-randomized controlled trial, planning to enroll 180 patients with pure native aortic regurgitation. On the basis of standardized medical therapy, patients will be assigned in a 1:1 ratio to undergo transfemoral transcatheter aortic va…
Phase: PHASE4 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Dual-Target CAR t therapy hopes to beat childhood leukemia
Disease control Recruiting nowThis study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in patients ≤ 21 years of age with recurrent/refractory…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to outsmart advanced prostate cancer
Disease control Recruiting nowASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New trial aims to shield blood cancer patients from deadly infections
Disease control Recruiting nowThis study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of d…
Phase: PHASE2, PHASE3 • Sponsor: Monash University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Smart radiation seeks out cancer cells in 8 tumor types
Disease control Recruiting nowPhase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for chagas: experimental drug aims to wipe out parasites
Disease control Recruiting nowThis study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could early use of stronger drugs transform mental health treatment?
Disease control Recruiting nowSchizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotr…
Phase: PHASE3 • Sponsor: Dr. Inge Winter • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for rare brain tumor: drug trial targets regrowth
Disease control Recruiting nowPrimary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with an…
Phase: PHASE1, PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Triple therapy shows promise for hard-to-treat liver cancer
Disease control Recruiting nowThe study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a tiny valve boost survival after cardiac arrest?
Disease control Recruiting nowThe goal of this clinical trial is to learn whether using Positive End-Expiratory Pressure (PEEP) during cardiopulmonary resuscitation (CPR) improves outcomes for adults who experience out-of-hospital cardiac arrest, a condition where the heart suddenly stops beating. PEEP is use…
Phase: PHASE3 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC